News

PDS0203 stands out among COVID-19 vaccines currently in development because it includes a vaccine technology pioneered by PDS Biotech called Versamune®, which stimulates important parts of the immune system to activate T cells.

Artemisia annua or "Sweet Annie" has been used as a medicinal herb for centuries. With potential to treat a variety of cancers & even COVID-19, this plant is more relevant than ever & UK is showing how we can take it from Kentucky fields to the lab to our patients.

UK researchers hope to gain a better understanding of the effects of COVID-19 on sleep and alcohol use so that we will be better prepared to prevent and treat psychological effects of COVID-19 pandemic or similar outbreaks in the future.

Any full-time UK undergraduate student of any major who has completed at least one semester of research with a faculty mentor is eligible to apply for a Summer Research Fellowship.

Dutch is leading the College of Medicine’s COVID-19 Unified Research Experts (CURE) Alliance team, which brings together faculty expertise from multiple disciplines across the university to focus on advising COVID-19 patient care and clinical trials based on emerging research.

CCTS is partnering with NCATS, the National Center for Data to Health, and around 60 other clinical institutions affiliated with the NCATS Clinical and Translational Science Awards Program to leverage big data in the fight against COVID-19.

The new potential treatment has been added to the University of Kentucky’s innovative clinical trial for experimental COVID-19 therapies, which was launched by leaders from UK’s Markey Cancer Center, College of Medicine and College of Pharmacy in May.

UK announced a research collaboration with Atomwise, an industry leader in using artificial intelligence (AI) for small molecule discovery, to explore potential COVID-19 therapies.

UK College of Medicine researchers are using the special antibodies made by alpacas, called nanobodies, to help understand the novel coronavirus and potentially develop a treatment that could protect people from being infected. 

Known as Serologic Testing to Accelerate Recovery and Transition (START), the study focuses on antibody testing to begin understanding how many people in the region may have already contracted and recovered from COVID-19.